Drug Profile
Tenofovir - CONRAD
Alternative Names: (R)-PMPA; GS 1278; PMPALatest Information Update: 05 Jan 2022
Price :
$50
*
At a glance
- Originator Centre for the AIDS Programme of Research in South Africa; Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
- Developer CONRAD; Gilead Sciences; Hanmi Pharmaceutical; National Institute of Allergy and Infectious Diseases
- Class Adenine nucleotides; Antiretrovirals; Phosphonic acids; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HIV infections
- No development reported Hepatitis B
Most Recent Events
- 12 Dec 2019 Johns Hopkins University and CONRAD plan the phase I DREAM-02 trial for HIV infections (Prevention) in USA in January 2020 (Rectal,Spray) (NCT04195776)
- 03 Dec 2018 CONRAD plans a phase II trial for HIV infections (Prevention) in December 2018 (NCT03762382)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in South Korea